Strengthening OS data heads into a BLA decision, but a going-concern flag raises the question of whether Summit survives a setback

Bull

FDA grants approval on the November 14 PDUFA date, accepting the updated June 2026 OS analysis (HR 0.76 in both ITT and western subgroups at 23.2 months median follow-up) as sufficient evidence of efficacy and geographic translatability. Approval would establish ivonescimab as a commercially viable second-line standard of care in EGFRm NSCLC post-TKI progression, unlock revenue generation, and relieve the going-concern overhang by improving Summit's access to capital markets.

Bear

The FDA declines to approve or issues a Complete Response Letter, most likely citing concerns about the predominantly Asian trial population (HARMONi enrolled largely in China) and the adequacy of the western patient dataset — only 23.2 months median follow-up in that subgroup — as insufficiently mature to establish benefit in a US label. A second failure mode is a manufacturing or Chemistry, Manufacturing and Controls deficiency unrelated to efficacy. Given Summit's flagged going-concern risk and the failed $500M equity raise, a rejection would severely constrain the company's ability to fund ongoing Phase III programs and operations.